Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Mirati Therapeutics (NASDAQ: MRTX) announced promising clinical data for adagrasib, a potent KRASG12C inhibitor, demonstrating efficacy in patients with advanced solid tumors such as pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancer (BTC). The findings, published in the Journal of Clinical Oncology and presented at the ASCO Plenary Series in April 2023, indicate an overall objective response rate (ORR) of 35%, with 33% for PDAC and 42% for BTC. Adagrasib's safety profile aligns with prior studies on NSCLC and CRC. This Phase 2 data from the KRYSTAL-1 study highlights adagrasib’s potential as a monotherapy, especially given its recent inclusion in the NCCN guidelines for CNS cancers, signaling a pathway toward regulatory approval for additional indications.
Mirati Therapeutics (NASDAQ: MRTX) will announce first quarter 2023 financial results on May 9, 2023, at 4:30 p.m. ET. The event will include corporate updates and a review of financial results. Investors can listen to the call via a live webcast on Mirati's website or by dialing specific U.S. and international phone numbers.
Mirati is committed to developing therapies for cancer, focusing on unmet needs in areas like lung cancer. The company is advancing several promising therapeutics, including KRAZATI® (adagrasib), which targets genetic drivers of cancer. However, investors are reminded that forward-looking statements in the release carry risks and uncertainties, including those associated with COVID-19 and drug development processes.